Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01523990 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
A Phase 1 study, sponsored by TaiGen Biotechnology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT01523990 is a Phase 1 study that has completed, run by TaiGen Biotechnology Co.. The registered enrollment target is 135 participants.
The verdict
NCT01523990, a Phase 1 study, has completed, sponsored by TaiGen Biotechnology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
Interventions
- DRUG placebo
- DRUG TG-2349
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01523990
The ClinicalTrials.gov registry entry for NCT01523990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiGen Biotechnology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01523990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01523990 about?
NCT01523990 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients". A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
What is the current status of trial NCT01523990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2011-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01523990?
The interventions under investigation include: placebo (DRUG), TG-2349 (DRUG).
Who is sponsoring clinical trial NCT01523990?
This trial is sponsored by TaiGen Biotechnology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.